IAMA Therapeutics
10:45 AM - 11:00 AM (EDT), Wednesday, June 7, 2023 ・ Session Room 104B
IAMA Therapeutics is a Series A- late preclinical-stage pharmaceutical company focused on discovering, developing, and commercializing novel medicines to make a difference in the lives of children suffering from neurodevelopmental disorders and neuropsychiatric conditions. IAMA Therapeutics couples emerging advances in drug discovery and neurobiology to build a leading, next-generation neuroscience pipeline to selectively inhibit the sodium-potassium chloride cotransporter and other therapeutic targets relevant to brain disorders characterized by neuronal imbalance.
The company's preclinical pipeline consists of the following chloride modulators: the lead candidate IAMA-6 for the treatment of idiopathic autism, refractory epilepsy, and Dravet syndrome; IAMA-097 for the treatment of secondary and rare forms of autism, and other candidates targeting cognitive decline.
The company's preclinical pipeline consists of the following chloride modulators: the lead candidate IAMA-6 for the treatment of idiopathic autism, refractory epilepsy, and Dravet syndrome; IAMA-097 for the treatment of secondary and rare forms of autism, and other candidates targeting cognitive decline.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Italy
Year Founded:
2021
Main Therapeutic Focus:
CNS/Neurological
Lead Product in Development:
IAMA-6
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Two
Speaker
